Recent Updates
Recently added Catalysts
RLMD

Relmada Therapeutics, Inc Proforma Balance sheet

Key Takeaway: June 30, 2019 Without Impact of Financing Pro Forma Adjustments Resulting from Financings Post Pro Forma Adjustments Assets: Current $ 9,984,381 $ 1,275,750 $ 11,260,131 Non-current $ 235,352 $ 235,352 Total Assets $ 10,219,733 $ 1,275,750 $

Full Press Release Details

June 30, 2019
Without Impact of Financing Pro Forma Adjustments Resulting from Financings Post Pro Forma Adjustments
Assets:
Current $ 9,984,381 $ 1,275,750 $ 11,260,131
Non-current $ 235,352 $ 235,352
Total Assets $ 10,219,733 $ 1,275,750 $ 11,495,483
Liabilities and stockholders' equity:
Current $ 2,606,418 $ - $ 2,606,418
Non-current $ - $ - $ -
Total Liabilities $ 2,606,418 $ - $ 2,606,418
Stockholders' equity $ 7,613,315 $ 1,275,750 $ 8,889,065
Total liabilites and stockholders' equity $ 10,219,733 $ 1,275,750 $ 11,495,483
Pro Forma adjustment is to account for the warrant exercise and Private Placement closed in September, 2019
Last updated: Oct 1, 2019